A novel biomarker test to predict therapy selection for Inflammatory Bowel Disease

一种预测炎症性肠病治疗选择的新型生物标志物测试

• 批准号: 104644
• 金额: $ 8.9万
• 依托单位: PREDICTIMMUNE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104644
• 关键词: novel; biomarker; test; predict; therapy

"Immune-mediated diseases, including autoimmune and inflammatory diseases, are common, debilitating and immensely heterogeneous: two patients diagnosed with the same disease may follow markedly different clinical courses. For many autoimmune diseases, effective and often expensive treatments are now available. However, the immunosuppression they induce also results in substantial side effects. Consequently, there is an increasing need for clinical assays that allow physicians to tailor these potentially toxic immunosuppressive therapies to the right patients at the right time. However, there are currently no robust clinical or biomarker assays that allow personalized therapeutic targeting in these diseases.PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with its first product addressing inflammatory bowel disease (both Crohn's disease and ulcerative colitis).In order to fully achieve the goal of personalized medicine in inflammatory bowel disease, it is necessary to demonstrate more than just prediction but also to show that clinical outcomes can be improved if aggressive therapy is matched to patients predicted to follow an aggressive disease course. This will be the goal of the feasibility study presented here."

免疫介导的疾病，包括自身免疫性疾病和炎症性疾病，是常见的、使人衰弱的、异质性极大的疾病：诊断为同一疾病的两名患者的临床病程可能明显不同。对于许多自身免疫性疾病，现在有了有效且往往昂贵的治疗方法。然而，它们诱导的免疫抑制也会导致严重的副作用。因此，对临床检测的需求日益增加，从而使医生能够在正确的时间为正确的患者量身定制这些潜在毒性的免疫抑制疗法。然而，目前还没有强大的临床或生物标志物检测方法可以实现这些疾病的个性化治疗靶向。PredictImmune正在开发用于指导免疫介导炎症性疾病治疗方案的开创性工具，其首款产品针对炎症性肠病（克罗恩病和溃疡性结肠炎）。为了充分实现炎症性肠病个体化治疗的目标，有必要证明不仅仅是预测，而且还需要证明，如果积极治疗与预测的侵袭性疾病病程相匹配，临床结果可以得到改善。这将是这里提出的可行性研究的目标。”